Daniel Besser

20070166710, Jul 19, 2007

Mar 31, 2004

10/551392

Markus Stoffel - New York NY, US
Christian Wolfrum - New York NY, US
David Shih - New York NY, US
Satoru Kuwajima - New York NY, US
Daniel Besser - New York NY, US

C12Q 1/68
G01N 33/53
A61K 48/00
A61K 38/17

435006000, 435007100, 514012000, 514044000

The present invention relates to methods for inhibiting adieogenesis and methods for treating obesity, metabolic syndrome and non-insulin dependent diabetes mellitus by administering an agent that increases Foxa-2 or Fxr, or an agent that activates Fxr. The invention is further related to methods for identifying agents that increase Foxa-2 or Fxr, or activate Fxr, and the use of such agents for treatment of obesity, metabolic syndrome and non-insulin dependent diabetes mellitus. Methods of identifying agents that mediate the phosphorylation of the transcription factor Foxa-2 are provided. Such agents are useful in methods of treating Type 2 diabetes.

6492124, Dec 10, 2002

Jun 11, 1999

09/330867

Brian Wong - New York NY
Daniel Besser - New York NY
Yongwon Choi - New York NY

The Rockefeller University - New York NY

G01N 33567

435 71, 514 2, 530350

The present invention relates to methods and compositions for modulating activity of a TRANCE receptor, including the modulation of TRANCE signaling activity. In particular, the invention provides screening methods by which novel modulators of TRANCE signaling may be identified, including TRANCE inhibitors, agonists and antagonists. The invention also relates to the identification of one or more specific pathways for osteoclast surivival, and the manipulation of this pathway (e. g. , using a TRANCE modulator of the invention). Such manipulation may provide strategies for treating osteoclast-related diseases such as osteoporosis and osteopetrosis.